Clinical trialNCT00380835WithdrawnPhase 2Interventional

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

SponsorCelgene CorporationEnrollment66Metastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Richard S Ungerleider, MD
Theradex
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
New Milford, Connecticut, United States
Facility name not stated
Sharon, Connecticut, United States
Facility name not stated
Torrington, Connecticut, United States
Facility name not stated
Burnsville, Minnesota, United States
Facility name not stated
Edina, Minnesota, United States
Facility name not stated
Maplewood, Minnesota, United States
Facility name not stated
Minneapolis, Minnesota, United States
Facility name not stated
Saint Paul, Minnesota, United States
Facility name not stated
Woodbury, Minnesota, United States
Facility name not stated
Columbia, Missouri, United States
Facility name not stated
Albany, New York, United States
Facility name not stated
Amsterdam, New York, United States
Facility name not stated
Hudson, New York, United States
Facility name not stated
Latham, New York, United States
Facility name not stated
Rexford, New York, United States
Facility name not stated
Schenectady, New York, United States
Facility name not stated
Troy, New York, United States
Facility name not stated
Asheville, North Carolina, United States
Facility name not stated
Dallas, Texas, United States
Facility name not stated
Dallas, Texas, United States
Facility name not stated
Dallas, Texas, United States
Facility name not stated
El Paso, Texas, United States
Facility name not stated
El Paso, Texas, United States
Facility name not stated
Houston, Texas, United States
Facility name not stated
Midland, Texas, United States
Facility name not stated
Odessa, Texas, United States
Facility name not stated
Plano, Texas, United States
Facility name not stated
Tyler, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Amrubicin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: —
Primary completion: —
Completion: 31 Dec 2007
Last update posted: 23 Sept 2008
Registered enrollment: 66
Registry id: NCT00380835

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.